Back to top
February 7, 2018
FDA grants breakthrough therapy designation for Dravet syndrome treatment
Research, Treatments, Pediatric Epilepsies

The FDA has granted Zogenix Inc. breakthrough therapy designation for low-dose fenfluramine use to treat seizures related to Dravet syndrome, according to a press release issued by the company.

“We are very pleased that the FDA has granted breakthrough therapy designation based on the efficacy and safety results from Study 1 reported in the fall of 2017,” Gail M. Farfel, PhD, chief development officer of Zogenix, said in the release. “We look forward to working closely with the FDA as we conclude our phase 3 clinical program in Dravet syndrome, a rare and catastrophic form of childhood epilepsy.

ZX008 can also be used for the treatment of Lennox-Gastaut syndrome, according to the release This form of epilepsy is also severe and begins in childhood. Those who have this condition are likely to also have intellectual disability.

Learn More

 

Related News

August 9, 2018
Crowdsourced Algorithms Predict Epilepsy Seizures

Thanks to the crowdsourcing of more than 10,000 algorithms from around the world, epileptic seizure prediction is possible in a wider range of...

Read More
August 9, 2018
Environmental Enrichment Alleviates Cognitive and...

[Researchers state] these findings suggest that environmental enrichment effectively ameliorates cognitive and behavioral deficits in EL mice....

Read More
August 9, 2018
Compound from Spider Venom Reduces Seizure Susceptibility,...

A CURE Grantee and other researchers discovered that a compound isolated from spider venom called Hm1a helps reduce seizure susceptibility and...

Read More